INT230-6

Phase 3Small molecule

IIntensity Therapeutics, Inc.

INT230-6 is one of 70 small molecule programs targeting Breast Cancer. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Breast CancerActive, not recruiting

Soft Tissue SarcomaActive, not recruiting

Breast CancerPhase 2

Active, not recruiting

Soft Tissue SarcomaPhase 3

Active, not recruiting

Competition

Competitive Landscape

2828 competitors in Breast Cancer

#DrugCompanyPhaseTrials

Trodelvy

Gilead

Preclinical

37 2

Tecentriq

Roche

Preclinical

36 3

Halaven

Eisai

Preclinical

38 4

INT230-6

IIntensity Therapeutics, Inc.

Phase 3

1 5

Gemzar

GGynecologic Oncology Group

Preclinical

22 6

Megace

Bristol-Myers Squibb

Preclinical

4 7

Blenoxane

Bristol-Myers Squibb

Preclinical

1 8

Tricor

JJagotec

Preclinical

1 9

Acupan

YYonsei University

Preclinical

1 10

Chantix

PPrism Pharmaceuticals

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2028

Phase 3Active, not recruiting

Soft Tissue Sarcoma

NCT06263231

Q4 2029

Phase 2Recruiting

Chemotherapy

NCT06358573

Clinical

Trials by Indication[1]

Phase 11 trial

A Phase 1/2 Safety Study of Intratumorally Dosed INT230-6

Completed·IIntensity Therapeutics, Inc.·Phase 1/2·NCT03058289·111 enrolled

Chemotherapy1 trial

Intratumoral INT230-6 Followed by Neoadjuvant Immuno-chemotherapy in Patients With Early TNBC. INVINCIBLE-4-SAKK

Recruiting·SSwiss Cancer Institute·Phase 2·NCT06358573·54 enrolled

Breast Cancer1 trial

INVINCIBLE TRIAL: Intratumoral INT230-6 in Breast Cancer

Unknown status·OOttawa Hospital Research Institute·Phase 2·NCT04781725·90 enrolled

Soft Tissue Sarcoma1 trial

A Study to Investigate Efficacy & Safety of Intratumoral INT230-6 Compared to US Standard of Care in Adults With Soft Tissue Sarcomas (INVINCIBLE-3)

Active, not recruiting·IIntensity Therapeutics, Inc.·Phase 3·NCT06263231·333 enrolled

Sources

References

[1]
ClinicalTrials.gov — 4 trial records for INT230-6. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — INT230-6 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for INT230-6. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Intensity Therapeutics, Inc. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: IIntensity Therapeutics, Inc.

INT230-6

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2028

Q4 2029

Trials by Indication[1]

Phase 11 trial

Chemotherapy1 trial

Breast Cancer1 trial

Soft Tissue Sarcoma1 trial

References

Drug Info

Quick Facts

Related News